Foundation for innovation
in Cardiometabolism and Nutrition

Research

  • IHU ICAN’s flagship actions in 2024 to combat cardiometabolic diseases

    IHU ICAN’s flagship actions in 2024 to combat cardiometabolic diseases

  • Discovery of the link between CD63 tetraspanin and cholesterol transport

    Discovery of the link between CD63 tetraspanin and cholesterol transport

  • Epicardial adipose tissue discovery: better prevention of atrial metabolic cardiomyopathy with MRI

    Epicardial adipose tissue discovery: better prevention of atrial metabolic cardiomyopathy with MRI

  • Results of the MAESTRO-NASH clinical trial: a new hope for the treatment of MASH (NASH) with liver fibrosis

    Results of the MAESTRO-NASH clinical trial: a new hope for the treatment of MASH (NASH) with liver fibrosis

  • A new diagnostic tool to improve MASH (NASH) clinical trials

    A new diagnostic tool to improve MASH (NASH) clinical trials

  • MEDITWIN: using digital twins to develop tomorrow’s personalized medicine

    MEDITWIN: using digital twins to develop tomorrow’s personalized medicine

  • IHU ICAN launches its barometer on cardiometabolic diseases with IFOP

    IHU ICAN launches its barometer on cardiometabolic diseases with IFOP

  • Type 2 diabetes: link between aortic flow and epicardial fat discovered

    Type 2 diabetes: link between aortic flow and epicardial fat discovered

  • How to optimize decision making for defibrillator implantation in hypertrophic cardiomyopathy?

    How to optimize decision making for defibrillator implantation in hypertrophic cardiomyopathy?

  • The SINBAD score, a useful tool for predicting major adverse foot events in diabetic patients?

    The SINBAD score, a useful tool for predicting major adverse foot events in diabetic patients?

ISO 9001 Certified

OUr Institutionnal Supporters

Our network